---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-273959"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:19:20.643971+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam reports positive Phase 3 BROADWAY topline: 33% LDL-C reduction, 21% MACE reduction

## Summary
- Primary endpoint met: LS mean LDL-C reduction of 33% (p<0.0001) vs placebo at day 84 on top of maximally tolerated therapies.
- Observed 21% reduction in MACE (exploratory endpoint) at one year; hazard ratio 0.79 (95% CI 0.54-1.15).
- Obicetrapib well-tolerated: TEAEs 59.8% vs placebo 60.9%; discontinuation 11.1% vs 12.4%.
- NewAmsterdam plans to present additional BROADWAY data at upcoming medical meetings and discuss filings with regulators.

## SEC filing metadata
- accession: 0001193125-24-273959
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524273959/0001193125-24-273959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524273959/d910195d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-273959
- JSON: https://secwatch.observer/filing/0001193125-24-273959.json
- Plain text: https://secwatch.observer/filing/0001193125-24-273959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.